Research progress in immunotherapy for advanced non-small cell lung cancer
Immune checkpoint inhibitors(ICIs)have shown significant benefits in the treatment of non-small cell lung cancer(NSCLC),and their individual or combination therapy has become the standard treat-ment option for advanced NSCLC.The article reviews immunotherapy regimens,efficacy,and safety for ad-vanced NSCLC patients,in order to provide theoretical support for patients to choose treatment options that benefit more.
Non small cell lung cancerImmune checkpoint inhibitorsReview
万方数据
维普
